Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03234985

Acronym

NUCLARA

Enrollment

Registered

2017-08-01

Start date

2017-07-01

Completion date

2021-10-25

Last updated

2022-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Brief summary

Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and consolidation. Standard chemotherapy combination for induction treatment associates cytarabine (AraC), a nucleoside analog, and an anthracycline (most often daunorubucin). About 60-70% of patients achieved complete remission after this standard chemotherapy. As cytarabine competes with endogenous nucleotides to exert its activity, the aim of this protocol is to study in vivo the effect of intracellular nucleotide pools on the efficacy of the induction treatment. Thus, intracellular nucleotides levels will be determined in peripheral blood mononuclear cells of patients with acute myeloid leukemia before treatment, and results will be compared with the efficacy of the treatment. This parameter will be assessed by the achievement of complete remission.

Interventions

BIOLOGICALBiological analyses

Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

Patients Inclusion Criteria: * age over 18 years * acute myeloid leukemia * standard induction chemotherapy with cytarabine and daunorubicin * patients who received the information and did not object to participate to the study Patients

Exclusion criteria

\- patients with acute myeloid leukemia 3 healthy volunteers Inclusion Criteria : * adults without known hematological disease, * adults who received the information and did not object to participate in the study healthy volunteers

Design outcomes

Primary

Measure	Time frame	Description
Complete remission	30 days	Primary endpoint will be the achievement of complete remission after induction treatment and bone marrow aplasia.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026